WuXi's STA in five-year supply deal with Tesaro

24 July 2017

STA Pharmaceutical, a division of WuXi AppTec which offers a small molecule pharmaceutical development and manufacturing capability and technology platform, has signed a supply agreement with US cancer drug developer Tesaro (Nasdaq: TSRO).

Under the five-year agreement, STA will provide supplies of certain starting and intermediate materials for the recently launched Zejula (niraparib) – an orally active and potent poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of ovarian cancer.

Zejula was approved for epithelial ovarian, fallopian tube or primary peritoneal cancer by the US Food and Drug Administration (FDA) on March 27, 2017, and is now available to patients in the USA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK